Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, a broad clinical and pre-clinical product pipeline and three proprietary next generation antibody technologies. Source
No articles found.
Axcella is designing and developing AXA Candidates, compositions of endogenous met...
Axcella is designing and developing AXA Candida...
Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy ...
Atara Biotherapeutics is a leading off-the-shel...
Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the...
Ritter Pharmaceuticals, Inc. develops novel the...
As a leading manufacturer of medical devices and components, Atrion makes a wide r...
As a leading manufacturer of medical devices an...
At Affimed, we are committed to improving outcomes for patients with cancer. Our s...
At Affimed, we are committed to improving outco...
iCAD, Inc. an industry-leading provider of advanced image analysis, workflow solut...
iCAD, Inc. an industry-leading provider of adva...
Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal a...
Immunomedics is a clinical-stage biopharmaceuti...
Headquartered in Mountain View, California, IGM Biosciences is a biotechnology com...
Headquartered in Mountain View, California, IGM...
Cellectis is a clinical-stage biopharmaceutical company that harnesses the immune ...
Cellectis is a clinical-stage biopharmaceutical...
Join the National Investor Network and get the latest information with your interests in mind.